Lord, Abbett & Co. LLC I Mab Transaction History

Lord, Abbett & Co. LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 09, 2021	SELL	$57.18 - $84.43 $3.97 Million - $5.86 Million	-69,355 Closed	0 $0
Q2 2021 Aug 11, 2021	SELL	$47.86 - $83.95 $1.24 Million - $2.18 Million	-25,919 Reduced 27.2%	69,355 $5.82 Million
Q1 2021 May 11, 2021	BUY	$44.38 - $63.97 $1.14 Million - $1.64 Million	25,704 Added 36.95%	95,274 $4.62 Million
Q4 2020 Feb 09, 2021	BUY	$32.94 - $47.15 $2.29 Million - $3.28 Million	69,570 New	69,570 $3.28 Million

15.5M

56.4K

5.8K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $74.8M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

Stay updated on Lord, Abbett & Co. LLC with notifications on news.